Last Updated: 21 November 2024
Converge Bio, a generative AI platform that’s changing drug discovery and development, has raised $5.5 million in seed funding. The round was led by TLV Partners, with support from other prominent investors. This funding is a key milestone for Converge Bio as they work to transform how biotech and pharmaceutical companies develop new drugs.
Investors believe in Converge Bio's potential to speed up the slow and costly process of bringing new drugs to market. Shahar Tzafrir, Managing Partner at TLV Partners, highlighted Converge Bio's innovative approach of treating biological data like a language, calling it a significant shift for the industry.
Developing new drugs is a complex and expensive process, often taking more than 10 years and costing around $1 billion. The risks are high, with 90% of drugs failing during clinical trials. Generative AI has the potential to change this by reducing both the time and cost involved. Converge Bio's platform uses large language models (LLMs) trained on biological data, such as DNA and RNA sequences, to make this process faster and more efficient.
The platform acts as a generative AI hub, delivering foundational models that can be used across biological languages.
"Just as ChatGPT can quickly generate meaningful responses, our AI models help us design optimized mRNA sequences for vaccines, saving months or even years in development time,"
Dov Gertz, co-founder and CEO of Converge Bio
The newly raised funds will primarily be used for product development. Converge Bio plans to improve its generative AI models and expand its data enrichment capabilities, making its platform more adaptable for biotech and pharmaceutical companies. The funding will also support collaborations with existing partners, including Teva, Compugen, and BiomX, to advance drug discovery projects focused on improving drug specificity and reducing side effects.
In addition, Converge Bio plans to expand its workforce by hiring experts in AI, machine learning, and biotechnology. The company is also looking to grow its partnerships within the biotech sector, allowing more companies to use AI to create better drugs faster and with greater accuracy.
Founded in 2024, Converge Bio is a generative AI platform aimed at speeding up drug discovery and development. The company is led by a team with deep scientific and technical knowledge: CEO Dov Gertz, an expert in bioinformatics, CTO Oded Kalev, a machine learning specialist, and Chief Scientific Officer Iddo Weiner, a biotech veteran. This diverse set of skills enables Converge Bio to bridge the gap between biological science and AI technology. Learn more about them at Converge Bio.
What makes Converge Bio stand out is its focus on providing predictive insights along with clear biological explanations. The platform's models are trained on extensive datasets, which allows for significant breakthroughs in drug development. By treating biological data as a language, Converge Bio helps scientists not only predict drug outcomes but also understand the reasons behind them. This approach reshapes how the biotech industry thinks about innovation and biological research.
The seed round was led by TLV Partners, a venture capital firm known for investing in bold and innovative startups. TLV Partners focuses on early-stage investments that have the potential to transform industries.
"Converge Bio's approach blew us away,"
Shahar Tzafrir, Managing Partner at TLV Partners
The firm's investment underscores the potential for AI to make drug discovery faster and more reliable, while also making the scientific processes behind it easier to understand. Learn more about TLV Partners at TLV Partners.
By using AI to create foundational biological models that can be adapted for specific needs, Converge Bio aims to significantly improve the quality and speed of new drug candidates—ultimately shaping the future of medicine.
